CLSA cuts target for Alibaba Health stock to HKD 3.70
Published on 10/15/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and revenue outlook
- CLSA cut its Alibaba Health target from HKD 4.70 to HKD 3.70 on October 2, 2026.
- Fiscal 2027 revenue growth guidance was reduced to 7 to 10 percent on October 2, 2026.
- Alibaba Health stock costs EUR 0.33 at Lang & Schwarz on October 15, 2026 at 8:03 p.m. CEST.
- Alibaba Health had a P/E ratio of 21.12 and a market capitalization of HKD 47.9 billion on October 15, 2026.
CLSA cut its target for Alibaba Health from HKD 4.70 to HKD 3.70 on October 2, 2026, while keeping its Outperform rating. The revised target is 25.00 percent above the HKD 2.96 closing price on the Hong Kong Stock Exchange on October 15, 2026, calculated in the same currency. Alibaba Health stock was trading at EUR 0.33 at Lang & Schwarz on October 15, 2026 at 8:03 p.m. CEST.
Revenue guidance points to slower growth
The outlook for fiscal 2027 is more restrained than the earlier plan. According to Sina Finance on October 2, 2026, management reduced revenue growth guidance from 10 to 15 percent to 7 to 10 percent for fiscal 2027. The same report said adjusted profit guidance remained between RMB 1.9 billion and RMB 2.3 billion.
The pressure is concentrated in health products and medical devices, while medicine sales continued to grow at a high double-digit rate in the first half of fiscal 2027, according to Sina Finance. Morningstar also reported on September 21, 2026 that first-half fiscal 2027 revenue growth was expected to slow to the high single digits from the midteens because of weaker health-product sales and medical-device demand.
Valuation and trading position
Alibaba Health closed at HKD 2.96 on the Hong Kong Stock Exchange on October 15, 2026. Its 52-week range was HKD 2.75 to HKD 7.91, placing the stock 62.58 percent below its high and 7.64 percent above its low. Trading volume reached 120,619,764 shares against an average of 74,822,336 shares.
The company had a market capitalization of HKD 47.9 billion and a P/E ratio of 21.12 on October 15, 2026. The dividend yield was 0.08 percent. The next scheduled corporate date is not included because a dated future reporting event was not substantiated.
Comparison with peers
Alibaba Health (HKEX, HKD): P/E 21.12, market capitalization HKD 47.9 billion
JD Health (HKEX, HKD): plus 1.62 percent, P/E 16.67, market capitalization HKD 120.4 billion
Ping An Healthcare (HKEX, HKD): plus 0.61 percent, P/E 22.54, market capitalization HKD 12.4 billion
Price stays below the yearly high
The Hong Kong listing's position inside its annual range remains the clearest market reference, with the stock 62.58 percent below its HKD 7.91 high on October 15, 2026. The lower end of the range was HKD 2.75.
Alibaba Health was trading at EUR 0.33 at Lang & Schwarz on October 15, 2026 at 8:03 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Alibaba Health stock.
Alibaba Health stock facts
- Company: Alibaba Health Information Technology Limited
- ISIN: BMG0171K1018
- Ticker: 0241.HK
- Primary exchange: HKEX
- Price Lang & Schwarz (as of October 15, 2026, 8:03 p.m. CEST): EUR 0.33
- Market capitalization: HKD 47.9 billion (as of October 15, 2026)
- 52-week range: HKD 2.75-7.91 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Information Services
Market context: Current market reports.
